How is cisatracurium different from other NMB agents for ARDS?

Cisatracurium is Hofmann elimination (spontaneous degradation at physiological pH/temperature) - no renal or hepatic metabolism required. This makes it safe in multi-organ failure. ACURASYS trial: 48h cisatracurium infusion for early severe ARDS (P/F <150) reduced adjusted 90-day mortality 25%. However, ROSE trial did not confirm benefit vs light sedation protocol.

When can cisatracurium infusion be stopped and how is reversal assessed?

Cisatracurium infusion is stopped when ARDS indication resolves (P/F >150 on FiO2 <0.6) or at 48h. After stopping: TOF monitoring starts. Neostigmine 0.04 mg/kg IV reverses at TOF 2+ (2 twitches present). Sugammadex 2 to 4 mg/kg is preferred if TOF low or spontaneous recovery slow, though sugammadex does not reverse benzylisoquinolines (use neostigmine for cisatracurium).

Cisatracurium Neuromuscular Blockade Reversal Assessment

Assess cisatracurium reversal readiness using train-of-four (TOF) ratio and guide neostigmine or sugammadex dosing for ICU patients post-neuromuscular blockade for ARDS or status asthmaticus.

Use the full interactive calculator below, or

Related Calculators

Rocuronium TOF

Medical Long-tail

Neostigmine Reversal Dose

Medical Long-tail

Cisatracurium Neuromuscular Blockade Reversal Assessment

Related Calculators

Frequently Asked Questions

How is cisatracurium different from other NMB agents for ARDS?

When can cisatracurium infusion be stopped and how is reversal assessed?